Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 401–500 of 648
Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder
Rentsch, C. T., Malone, S. G., Shi, M., Setzer, M. R., Piserchia, Z., Winterlind, E. L., Farokhnia, M., Tazare, J., Justice, A. C., Fiellin, D. A., et al. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70247 · Cited by 3
Ang, M. Y., Chen, L., Song, L., Lipovich, L., & Choo, S. W. (2026) · Biomolecules · doi:10.3390/biom16071029 · Cited by 2
Genome-wide association study biomarkers in bipolar disorder
Medeiros, G. C., & Goes, F. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821398-8.00016-3 · Cited by 2
“Mendelian Code” in the Genetic Structure of Common Multifactorial Diseases
Nazarenko, M. S., Sleptcov, A. A., & Puzyrev, V. P. (2022) · Russian Journal of Genetics · doi:10.1134/s1022795422100052 · Cited by 2
Study of effect modifiers of genetically predicted CETP reduction
Legault, M., Barhdadi, A., Gamache, I., Lemaçon, A., Perreault, L. L., Grenier, J., Sylvestre, M., Hussin, J., Rhainds, D., Tardif, J., et al. (2023) · Genetic Epidemiology · doi:10.1002/gepi.22514 · Cited by 3
Quaternary-Child Crossover for Genetic Algorithm in Real-Time Scheduling Optimization
(2023) · International journal of intelligent engineering and systems · doi:10.22266/ijies2023.0430.09 · Cited by 2
Cardioinformatics Advancements in Healthcare and Biotechnology
Khomtchouk, B. B. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004119 · Cited by 2
Toward the Next Generation of Precision Medicine
Verhulst, B., & Benstock, S. E. (2023) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/23727322231197765 · Cited by 2
Drug classes affecting intracranial aneurysm risk: Genetic correlation and Mendelian randomization
Ruigrok, Y. M., Veldink, J. H., & Bakker, M. K. (2024) · European Stroke Journal · doi:10.1177/23969873241234134 · Cited by 2
Chen, L., Zhang, Y., Feng, Q., Yao, K., Zheng, L., Yang, Y., Zheng, W., Li, F., Lv, Y., & Cai, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79906-x · Cited by 2
Yang, N., Di, J., Han, X., Zhang, W., Cui, X., & Feng, H. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05854-5 · Cited by 2
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future
Landouré, G., Yalcouyé, A., Diarra, S., Maīga, A. B., Dembélé, M. E., Cissé, C. A. K., Bocoum, A., Cissé, L., Bamba, S., Samassékou, O., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01098-3 · Cited by 2
Hope vs Hype II: We should stop embarking on epidemiology-based disease modifying clinical trials
Espay, A. J., Piccinin, C. C., & Schwarzschild, M. A. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107904 · Cited by 1
Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy
Sánchez‐Jiménez, P., Alonso, L., Cerrada‐Gálvez, L., Elizalde-Horcada, M., Granero‐Cremades, I., Maietta, P., Gómez‐Martín, A., Abad‐Santos, F., Torres, C. V., de Toledo, M., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178146 · Cited by 3
Yi, M., Feng, X., Guan, Q., Liu, Y., Liu, Y., & Su, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07086-x · Cited by 2
Lim, D., & Kim, H. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.239 · Cited by 2
Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation
Poppelaars, F., Eskandari, S. K., Damman, J. J., Frazer‐Abel, A. A., Holers, V. M., Dixon, B. P., Daha, M. R., Sanders, S., Seelen, M. A., Faria, B., et al. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001675 · Cited by 2
The Fabulous Impact of CRISPR Method in Sickle Cell Disease Treatment
Ebrahimi, V., & Hashemi, A. (2021) · Trends in Peptide and Protein Sciences · doi:10.22037/tpps.v6i.34202 · Cited by 2
Gene Signature-Based Drug Repositioning
Jia, Z., Song, X., Shi, J., Wang, W., & He, K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101377 · Cited by 4
How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside
Piras, D., Lepori, N., Cabiddu, G., & Pani, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020193 · Cited by 2
Genetic Association Study Advances Idiopathic Pulmonary Fibrosis Pathophysiology and Health Equity
Hobbs, B. D. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202203-0612ed · Cited by 2
Clinical Advancement ForecastingPreprint
Czech, E., Wojdyla, R., Himmelstein, D. S., Frank, D., Miller, N., Milwid, J. M., Kolom, A., & Hammerbacher, J. (2024) · medRxiv · doi:10.1101/2024.08.02.24311422 · Cited by 3
Lalagkas, P. N., & Melamed, R. (2025) · medRxiv · doi:10.1101/2025.05.13.25327511 · Cited by 2
The root cause: why do so many drugs fail to translate from bench to bedside?
Levchenko, A., Corrigan, M., & Wexler, B. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2665217 · Cited by 2
SuperAger Initiative: unlocking the genetic potential of exceptional longevity
Milman, S., Barzilai, N., Wilson, K. A., van der Willik, O., Lederman, S., Perls, T. T., Gao, T., Leahy, A. M., Jain, P., Montgomery, A. H., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00429-7 · Cited by 1
The Genetics of Alcohol-Related Liver Disease
Innes, H. A., & Stickel, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_52 · Cited by 2
Unveiling new genetic insights in rheumatoid arthritis for drug discovery through Taxonomy3 analysis
Kozlowska, J., Humphryes-Kirilov, N., Pavlovets, A., Connolly, M., Kuncheva, Z., Horner, J., Manso, A. S., Murray, C. M., Fox, J., & McCarthy, A. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-64970-0 · Cited by 1
Using gene or cell therapies to treat Huntington's disease
Binda, C. S., Lelos, M. J., Rosser, A., & Massey, T. H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00014-9 · Cited by 2
Feng, W., Zhang, Y., Wu, Y., Wu, Z., Liu, J.-Y., & Xu, P. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118959 · Cited by 2
An Ocular Gene-Set Expression Library for Heritability Partition and Cell Line Enrichment Analyses
Hysi, P. G., & Hammond, C. J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.3.11 · Cited by 1
Can AI reveal the next generation of high-impact bone genomics targets?
Greene, C. S., Gignoux, C. R., Subirana-Granés, M., Pividori, M., Hicks, S. C., & Ackert‐Bicknell, C. L. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101839 · Cited by 1
Precision medicine in the pediatric and neonatal intensive care units through genomics
Duy, P. Q., Dylik, B., & Deniz, E. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001471 · Cited by 1
Guo, T., Zhang, J., Xu, X., Liu, D., Jia, G., Liu, X., & Xie, H. (2025) · Otology & Neurotology · doi:10.1097/mao.0000000000004574 · Cited by 1
Yu, K., Jiang, R., Yang, S., Huo, J., Zhou, D., & Zhao, Z. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf145 · Cited by 1
Zhou, H., Chen, R., Deng, Z., & Li, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04580-3 · Cited by 1
Xiao, Z., Liu, X., Tang, W., Lv, Y., Zhang, T., Zhan, X., Sun, Q., Omindo, W. W., Wang, Q., Zhang, R., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00829-3 · Cited by 2
Yao, R., Lu, Y., Lu, D., Ren, H., Wang, X., Lin, B., Chen, S., Zhu, Y., Chen, F., Wang, Y., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00826-6 · Cited by 1
Integration of genetic evidence to identify approved drug targets
Moix, S., Sadler, M. C., & Kutalik, Z. (2026) · Genome Medicine · doi:10.1186/s13073-026-01689-9 · Cited by 3
Ke, K., Zhou, Q., & Zhong, J. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.10.38 · Cited by 1
Integrated analysis for drug repositioning in migraine using genetic evidence and claims database
Inokuchi, S., & Tajima, T. (2025) · Frontiers in Big Data · doi:10.3389/fdata.2025.1677167 · Cited by 1
Genetic Targets, Financial Creativity: BridgeBio’s Model for Sustainable Drug Development
Shukla, C. G., Tendler, I., Kumar, N., & Lo, A. W. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104583 · Cited by 3
Proteome-wide association study identifies novel Alzheimer's disease-associated proteins
Sun, L., Wei, G., Ji, F., Ding, Y., Fan, J., Xu, Y., He, C., Zhou, Y., Liu, Z., Sun, Z., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251409352 · Cited by 1
Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
Zhang, C., Konigsberg, I. R., He, Y., Zhang, J., Chikowore, T., Feldman, W. B., Hu, X., Ding, Y., Paşaniuc, B., Chang, D., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.199951 · Cited by 1
Zhou, H., Wang, Z., Tan, Z., Deng, B., Yang, W., Huang, Z., Guo, X., Li, J., Wang, X., Yu, Y., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106183 · Cited by 1
Dang, X., Wang, Q., Zhang, C., Yao, L., Su, H., Yang, C. X., Feng, H., She, C. H., Chen, X. X., Yang, X. T., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01487-9 · Cited by 2
Mo, X., Sun, D., Li, F., Wang, D., & Liao, Y. (2026) · The FASEB Journal · doi:10.1096/fj.202504837r · Cited by 1
Multi-omics uncovers the pleiotropic genetic mechanisms linking MASLD and cardiometabolic syndromes
Yin, K., Zhang, C., Liu, B., Xu, R., Zeng, J., Eslam, M., & Ni, J. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03180-6 · Cited by 2
Migraine immune cell gene targets and their relationship to psychiatric disorders
Mo, X., Sun, D., Li, F., Wang, D., Deng, Y., Liao, Y., Yang, X., & Zhao, H. (2026) · The Journal of Headache and Pain · doi:10.1186/s10194-026-02465-1 · Cited by 1
Seow, S. W., Mina, T. H., Hebrard, M., Sadhu, N., Bellis, C., Lin, B. C. A., Jain, P., Vincent-Goy, P., Wang, X., Low, P. Y., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02687-8 · Cited by 2
The role of interleukin 6 in the development of cardiovascular pathology
Nasonov, E. L., Fomicheva, O. A., Baranov, A. A., Попкова, Т. В., & MIu, S. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-335-357 · Cited by 1
Positive selection screen identifies natural product β-catenin inactivators
Boudreau, M. W., Freire, V. F., Corbett, S. C., Martínez-Fructuoso, L., Shenoy, S. R., Yu, W., Kumar, R., Thornburg, C. C., Akee, R. K., Peyser, B. D., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2625189123 · Cited by 1
Rentsch, C. T., Palzes, V. A., Shi, M., Setzer, M. R., Malone, S. G., Kline‐Simon, A. H., Piserchia, Z., Winterlind, E. L., Leggio, L., Re, V. L., et al. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70487 · Cited by 1
Implications of genome plasticity for drug development
López‐León, S., González‐Giraldo, Y., Ruiter-Lopez, L., & Wegman-Ostrosky, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817819-5.00014-0 · Cited by 1
Antisense oligonucleotide drugs for neurological and neuromuscular disease
Lane, R. M., & Bennett, C. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00017-9 · Cited by 1
Target Validation—Prosecuting the Target
Jones, L. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00014-1 · Cited by 1
Perée, H., Петров, В. А., Tokunaga, Y., Kvasz, A., Farnir, F., Vieujean, S., Regimont, S., Mni, M., Wéry, M., Azarzar, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76672-4 · Cited by 1
Poduri, A., & Khanna, A. (2021) · Springer eBooks · doi:10.1007/978-981-15-5534-3_9 · Cited by 1
Schmidt, M. F. (2022) · Springer eBooks · doi:10.1007/978-3-662-64412-6_6 · Cited by 1
Pooled CRISPR KO Screens for Target Identification
Grotz, A. K., & Deswal, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch8 · Cited by 1
Schmidt, M. F. (2020) · Springer eBooks · doi:10.1007/978-3-662-61116-6_6 · Cited by 1
The Emerging Role of AI in Dementia Research and Healthcare
Ranson, J. M., Bucholc, M., Lyall, D. M., Newby, D., Winchester, L. M., Oxtoby, N. P., Veldsman, M., Rittman, T., Marzi, S. J., Skene, N., et al. (2022) · Brain informatics and health · doi:10.1007/978-981-19-5272-2_4 · Cited by 1
From Calcium Channels to New Therapeutics
McDonough, S. I. (2022) · Springer eBooks · doi:10.1007/978-3-031-08881-0_27 · Cited by 1
Drug Approval Prediction using Patents
Kamijo, K., Mitsumori, Y., Kato, H., & Kato, A. (2023) · Portland International Conference on Management of Engineering and Technology (PICMET) · doi:10.23919/picmet59654.2023.10216836 · Cited by 1
Target Validation for Medicinal Chemists
Thomas, M. J., & Ewart, L. C. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00653 · Cited by 1
Wang, F., Ruan, W., Yin, Q., & Zhu, L. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-07077-8 · Cited by 2
Proof-of-Concept of a DNA-Based Recording System for High-Throughput Functional Gene Screening
Kato, S., Ikemoto, A., Isayama, J., Takimoto, T., Saya, H., & Hamada, K. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00671 · Cited by 1
Gu, S., Zeng, S.-L., Zhang, W., Shen, C., Yuan, C., Song, Y., & Ye, Q. (2025) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100608 · Cited by 2
Leveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes
Hjelholt, A. J., Gholipourshahraki, T., Bai, Z., Shrestha, M., Kjølby, M., Sørensen, P., & Rohde, P. D. (2025) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00392-z · Cited by 1
Schuermans, N., Chehadeh, S. E., Hemelsoet, D., Bogaert, E., Debackere, E., Hilbert, P., Doninck, N. V., Taquet, M., Rosseel, T., Clercq, G. D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.15.439941 · Cited by 1
Friedman, C. E., Cheetham, S. W., Mills, R. J., Ogawa, M., Redd, M. A., Chiu, H. S., Shen, S., Sun, Y., Mizikovsky, D., Bouveret, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.17.488603 · Cited by 1
Poppelaars, F., da Costa, M. G., Faria, B., Eskandari, S. K., Petr, V., Holers, V. M., Daha, M. R., Berger, S. P., Damman, J. J., Seelen, M. A., et al. (2023) · medRxiv · doi:10.1101/2023.10.24.23297481 · Cited by 1
Locus-specific stratification and prioritization unveil high risk genes underlying hyperuricemiaPreprint
Zhang, J., Guo, Y., Gong, L., Xia, L., Liu, Q., Wang, K., Wang, Q., Liu, Z., Qin, Z. S., Shi, S., et al. (2024) · medRxiv · doi:10.1101/2024.03.06.24303846 · Cited by 1
Hébert-Milette, I., Lévesque, C., Paquette, J., Rivard, M.-È., Villeneuve, L. R., Boucher, G., Goyette, P., Charron, G., & Rioux, J. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643205 · Cited by 1
Kvastad, L., Kollotzek, A., Saghaleyni, R., Chang, C. J., Cao, T., & Lappalainen, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651876 · Cited by 1
Johansen, V. B. I., Lund, J. T., Romero-Lado, M. J., Breum, A. W., Svendsen, C., Jørgensen, K. S., Miller, R. L., Fritzen, A. M., Kilpeläinen, T. O., Schjoldager, K. T.-B. G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.12.688143 · Cited by 1
Verhulst, B., Harris, J., Adams, A. M., Benstock, S. E., Tong, C. W.-C., Case, A. J., & Hettema, J. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.04.703692 · Cited by 1
Ravarani, C. N. J., Arend, M., Baukmann, H. A., Cope, J. L., Lamparter, M. R. J., Sullivan, J. K., Fudim, R., Bender, A., Mälarstig, A., & Schmidt, M. F. (2026) · medRxiv · doi:10.64898/2026.02.19.26346536 · Cited by 1
Impact of proteogenomic evidence on clinical successPreprint
Karim, M. A., Hukku, A., Ariano, B., Holzinger, E. R., Tsepilov, Y. A., Hayhurst, J. D., Buniello, A., McDonagh, E. M., Castel, S. E., Nelson, M. R., et al. (2026) · medRxiv · doi:10.64898/2026.02.23.26346731 · Cited by 1
Paterson, V. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2606.14823 · Cited by 1
Li, J., Shringarpure, S., Wong, E., & Ho, A. (2026) · doi:10.64898/2026.06.29.735386
Genetic epidemiology of endometrial cancer
Kho, P. F. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.211383
CRISPR screens identify gene targets and drug repositioning opportunities at breast cancer risk lociPreprint
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., Hatzipantelis, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.07.459221
Иванович, Ц. И. (2012) · CyberLeninK (CyberLeninka)
CRISPR screens identify gene targets and drug repositioning opportunities at breast cancer risk lociPreprint
Rosenbluh, J., Tuano, N., Beesley, J. M., Manning, M., Shi, W., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1223972/v1
Mignon, L., Doan, K., Murphy, M. J., Elder, L., Yun, C., Milton, J., Sasaki, S., Hart, C. E., Montenegro, D., Allen, N., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106819
Mendelian Randomization of Circulating Proteome Identifies Actionable Targets in Heart FailurePreprint
Moncla, L.-H. M., Mathieu, S., Bossé, Y., Thériault, S., Arsenault, B. J., & Mathieu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1547537/v1
Developing clinically translatable screens using iPSC-derived neural cells
Engle, S. J., Faloon, P. W., Mariga, A., & Kleiman, R. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822277-5.00011-0
On the way to translate GWAS into kidney disease mechanisms
Devuyst, O., & Kiryluk, K. (2022) · Kidney International · doi:10.1016/j.kint.2022.10.004
Kostić, M., & Jones, L. H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch15
Harnessing AI and Genomics to Accelerate Drug Discovery
Feizi, A., & Gutierrez, J. M. (2022) · Future of business and finance · doi:10.1007/978-3-030-99838-7_5 · Cited by 1
The Human Genome Is Not Enough
Zehnder, A. M. (2023) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.43.01.13
Review: Mendelian randomization as a tool to inform drug development using human genetics — R1/PR7
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr7
Review: Mendelian randomization as a tool to inform drug development using human genetics — R1/PR8
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr8
Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr6
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr4
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr9
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr10
Decision: Mendelian randomization as a tool to inform drug development using human genetics — R0/PR5
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr5
Review: Mendelian randomization as a tool to inform drug development using human genetics — R0/PR2
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr2
Review: Mendelian randomization as a tool to inform drug development using human genetics — R0/PR3
Daghlas, I., & Gill, D. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr3
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.